Weiss Ratings Reaffirms "Sell (D-)" Rating for Septerna (NASDAQ:SEPN)

Key Points

• Weiss Ratings has reaffirmed a "Sell (D-)" rating for Septerna (NASDAQ:SEPN) in a recent report, which reflects ongoing concerns regarding the company's stock performance.
• Despite the negative rating from Weiss, other analysts like Cantor Fitzgerald have given Septerna an "overweight" rating with a target price of $25.00, indicating a divide in analyst sentiment.
• Septerna reported a significant earnings miss with a loss of ($0.56) EPS, falling short of estimates by ($0.51), and generated revenue of only $0.12 million against an expected $22.50 million.

Septerna (NASDAQ:SEPN - Get Free Report)'s stock had its "sell (d-)" rating restated by equities research analysts at Weiss Ratings in a research report issued to clients and investors on Wednesday,Weiss Ratings reports.

A number of other analysts have also issued reports on SEPN. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $25.00 target price on shares of Septerna in a report on Friday, September 5th. Wall Street Zen raised Septerna from a "sell" rating to a "hold" rating in a report on Sunday, September 21st. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $26.00 target price on shares of Septerna in a report on Thursday, August 21st. Four analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company's stock. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and a consensus target price of $26.75.

Septerna Stock Performance

Shares of SEPN stock opened at $22.49 on Wednesday. The stock's 50 day simple moving average is $14.39 and its 200 day simple moving average is $10.83. Septerna has a twelve month low of $4.17 and a twelve month high of $28.99. The company has a market capitalization of $1.00 billion and a price-to-earnings ratio of -2.23.

Septerna (NASDAQ:SEPN - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.51). The business had revenue of $0.12 million during the quarter, compared to analyst estimates of $22.50 million. Septerna had a negative net margin of 12,053.03% and a negative return on equity of 31.52%. On average, analysts forecast that Septerna will post -7.11 EPS for the current fiscal year.

Institutional Trading of Septerna

Several institutional investors have recently modified their holdings of the company. JPMorgan Chase & Co. grew its holdings in shares of Septerna by 15.0% during the 2nd quarter. JPMorgan Chase & Co. now owns 10,101 shares of the company's stock worth $107,000 after purchasing an additional 1,315 shares in the last quarter. Rhumbline Advisers grew its holdings in shares of Septerna by 16.6% during the 1st quarter. Rhumbline Advisers now owns 23,318 shares of the company's stock worth $135,000 after purchasing an additional 3,323 shares in the last quarter. Deutsche Bank AG grew its holdings in shares of Septerna by 53.3% during the 1st quarter. Deutsche Bank AG now owns 15,968 shares of the company's stock worth $92,000 after purchasing an additional 5,549 shares in the last quarter. Rangeley Capital LLC boosted its stake in Septerna by 10.7% in the 2nd quarter. Rangeley Capital LLC now owns 58,605 shares of the company's stock valued at $619,000 after buying an additional 5,655 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new stake in Septerna in the 1st quarter valued at $49,000.

About Septerna

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.